[Expression of sex hormone receptor in gastric cancer with synchronous ovarian metastasis and its significance].
To explore the clinicopathological characteristics of gastric cancer with synchronous ovarian metastasis and the significance of expression of sex hormone receptors. We retrospectively collected 31 cases of gastric cancer with synchronous ovarian metastasis from January 2002 to December 2012 from First and Third Affiliated Hospitals, Anhui Medical University as the test group. Then the expressions of estrogen receptor alpha (ERα), estrogen receptor beta (ERβ), progesterone receptor (PR) and androgen receptor (AR) in primary and metastatic lesions were detected by pathology and immunohistochemistry. Meanwhile 31 female gastric cancer patients without ovarian metastasis during the same period and at the same hospital designated as the control group. And their clinicopathological data were analyzed. As compared with the control group, the primary lesions of the test group had significant differences in age, tumor gross type, pathological type, degree of differentiation, depth of tumor invasion, peritoneal implantation and vascular thrombosis (all P < 0.05). The expressions of ERα, ERβ, PR and AR in primary tumors of the test group were 48.4% (n = 15), 38.7% (n = 12), 41.9% (n = 13), 32.3% (n = 10) versus 22.6% (n = 7), 64.5% (n = 20), 16.1% (n = 5) and 41.9% (n = 13) in the control group. The expressions of ERα,ERβ and PR in two groups were statistically significant (all P < 0.05) . The expressions of ERα and PR were positively correlated (P < 0.05) while there was no correlation between the others in test group (both P > 0.05). The strengthened expressions of ERα and PR and a missing expression of ERβ may be a crucial factor in gastric carcinogenesis with synchronous ovarian metastasis.